Medical device giant Abbott reveals Access study results demonstrating the benefits of MitraClip therapy in "real world" patients with mitral valve regurgitation, winning a note in the European Society of Cardiology's 2012 Heart Failure Guidelines.

Health care giant Abbott (NYSE:ABT) released new study results at this this year's European Society of Cardiology 2012 Congress in Germany, touting positive outcomes for its MitraClip mitral valve in "real world" patients.

The Access study included more than 560 patients who weren't good candidates for surgical valve repair, which is still considered the best option for eligible patients suffering from mitral valve regurgitation.